Journal Scans
Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): A Randomised, Open-Label, Multicentre, Phase 3 Trial
Lapatinib + Trastuzumab for HER2-Positive Early Breast Cancer
J Baselga, I Bradbury, M Piccart-Gebhart, H Eidtmann, et al
20120016
2012 Jan 16
Lancet
Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer (NeoALTTO): A Randomised, Open-Label, Multicentre, Phase 3 Trial
Lancet. 2012 Jan 16;[Epub Ahead of Print], J Baselga, I Bradbury, M Piccart-Gebhart, H Eidtmann, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.Methods: In this parallel groups, randomised, open-label, phase 3 study undertaken between Jan 5, 2008, and May 27, 2010, women from 23 countries with HER2-positive primary breast...
